PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
Scientific relevance. Cardiovascular diseases (CVD) are the leading cause of death worldwide. Dyslipidemia, as the pathophysiological basis of atherosclerosis, is the most important cause of CVD. Among the factors that modify this pathology, the World Health Organisation lists statins, which effecti...
Main Authors: | A. A. Nekipelova, R. N. Alyautdin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2023-09-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/369 |
Similar Items
-
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023-09-01) -
PCSK9: NEW VICTORY AND HORIZONS
by: M. O. Smolina, et al.
Published: (2018-09-01) -
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
by: Yehuda Handelsman, et al.
Published: (2018-07-01) -
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)